22q11.2 Deletion Syndrome is a genetic disorder caused by a microdeletion on chromosome 22, leading to diverse clinical features affecting multiple organ systems.
Understanding 22q11.2 Deletion Syndrome- GeneReviews Summary
22q11.2 Deletion Syndrome (22q11.2DS), also known as DiGeorge syndrome or velocardiofacial syndrome, results from a small missing segment on the long arm of chromosome 22 at position q11.2. This microdeletion disrupts several genes essential for normal development, causing a wide range of symptoms that vary significantly in severity and presentation.
This syndrome is one of the most common microdeletion syndromes, with an estimated incidence of about 1 in 4,000 live births. The deletion typically spans approximately 3 million base pairs but can be smaller or larger in some cases. It occurs sporadically in most individuals but can be inherited in an autosomal dominant pattern.
Genetic Mechanisms Behind the Deletion
The 22q11.2 region contains low copy repeats (LCRs), which are highly similar DNA sequences that predispose the chromosome to misalignment during meiosis. This misalignment leads to non-allelic homologous recombination, causing deletions or duplications.
The most common deletion spans about 3 Mb and includes approximately 30 to 40 genes, many involved in embryonic development, especially of the heart, thymus, parathyroid glands, and craniofacial structures.
Clinical Features and Spectrum
The phenotypic expression of 22q11.2DS is highly variable, ranging from mild learning difficulties to severe congenital anomalies. It affects multiple systems:
Cardiac Anomalies
Congenital heart defects are present in about 75% of affected individuals. The most frequent cardiac issues include conotruncal malformations such as:
- Tetralogy of Fallot
- Interrupted aortic arch type B
- Truncus arteriosus
- Ventricular septal defects (VSD)
These defects often require surgical correction early in life and significantly impact morbidity and mortality.
Immunodeficiency and Thymic Hypoplasia
The thymus gland is often underdeveloped or absent, leading to varying degrees of T-cell immunodeficiency. This can result in increased susceptibility to infections during infancy and childhood.
Some patients have mild immune dysfunction that improves with age; others may require specialized care for severe immunodeficiency.
Hypoparathyroidism and Calcium Regulation
Parathyroid gland hypoplasia causes hypocalcemia due to reduced parathyroid hormone (PTH) secretion. Symptoms range from mild tingling to life-threatening seizures related to low calcium levels.
Hypocalcemia often presents during the neonatal period but can also appear later.
Craniofacial and Palatal Abnormalities
Characteristic facial features assist clinical suspicion:
- Long face with prominent nose
- Small chin (micrognathia)
- Widely spaced eyes (hypertelorism)
- Ear anomalies such as low-set ears
Palatal abnormalities like velopharyngeal insufficiency or cleft palate occur frequently, leading to speech difficulties and feeding problems.
Neurodevelopmental and Psychiatric Manifestations
Developmental delays and learning disabilities are common, with many children experiencing speech delay and mild intellectual disability.
Psychiatric disorders such as attention deficit hyperactivity disorder (ADHD), anxiety disorders, autism spectrum disorder (ASD), and later onset schizophrenia occur at higher rates compared to the general population.
Molecular Diagnosis Techniques
Accurate diagnosis is essential for management and genetic counseling. Several molecular methods detect the typical deletion:
| Diagnostic Method | Description | Sensitivity & Specificity |
|---|---|---|
| Fluorescence In Situ Hybridization (FISH) | Uses fluorescent probes targeting the 22q11.2 region on metaphase chromosomes. | High sensitivity for common deletions; may miss atypical smaller deletions. |
| Multiplex Ligation-dependent Probe Amplification (MLPA) | Detects copy number changes across multiple exons within the region. | Highly sensitive; detects typical and atypical deletions effectively. |
| Chromosomal Microarray Analysis (CMA) | Genome-wide screening for copy number variants including microdeletions. | The gold standard; detects typical/atypical deletions with high resolution. |
Genetic testing should be performed on peripheral blood samples after clinical suspicion is raised based on phenotype.
Treatment Approaches Tailored to Symptoms
No cure exists for 22q11.2DS itself; treatment focuses on managing symptoms through multidisciplinary care:
Surgical Interventions for Cardiac Defects
Early cardiac surgery improves survival rates dramatically. Pediatric cardiologists coordinate timing based on defect type and patient condition.
Treatment of Hypocalcemia
Calcium supplementation combined with active vitamin D analogs manages hypoparathyroidism effectively.
Regular monitoring of serum calcium levels prevents complications such as seizures or cardiac arrhythmias.
Mental Health Monitoring and Intervention
Early recognition of psychiatric symptoms allows timely psychiatric care including counseling, behavioral therapies, and medication when necessary.
Ongoing psychological support improves quality of life substantially for affected individuals and their families.
The Importance of Genetic Counseling in 22q11.2 Deletion Syndrome- GeneReviews Summary
Genetic counseling plays a pivotal role due to variable inheritance patterns:
- Sporadic Cases: Most deletions occur de novo without prior family history.
- Familial Cases: Approximately 10% inherit the deletion from an affected parent.
- Prenatal Testing: Available via chorionic villus sampling or amniocentesis when family history exists or fetal anomalies are detected by ultrasound.
- Recurrence Risk: For de novo cases, risk is low but not zero due to germline mosaicism; familial cases carry a 50% chance per pregnancy.
- Counseling Focus: Educating families about variability in expression helps set realistic expectations.
Genetic counseling sessions should involve detailed family history analysis alongside psychological support due to potential emotional impacts related to diagnosis uncertainty.
Differential Diagnosis Considerations
Several syndromes share overlapping features with 22q11.2DS; distinguishing them aids accurate diagnosis:
- Kabuki Syndrome: Facial dysmorphism plus intellectual disability but no typical cardiac defects seen here.
- Noonan Syndrome: Congenital heart defects present but distinctive facial features differ.
- Phelan-McDermid Syndrome: Intellectual disability predominant without characteristic cardiac or immune involvement.
- CATCH-22:A historical term sometimes used synonymously but less precise than current nomenclature focusing specifically on chromosomal deletion.
Molecular testing remains definitive for confirming diagnosis amid phenotypic overlap with other syndromes.
Lifelong Management Challenges and Prognosis Insights
With advances in early detection and medical intervention, life expectancy has improved substantially compared to decades ago when many children died young from cardiac complications or infections.
However, lifelong challenges persist including:
- The need for ongoing multidisciplinary follow-up involving cardiology, endocrinology, immunology, speech therapy, psychiatry, and genetics specialists.
- The risk of developmental delays impacting social integration requiring tailored educational plans.
- The emergence of late-onset psychiatric disorders necessitating vigilance into adulthood.
- A requirement for family support networks due to chronic nature of care demands.
Despite these hurdles, many individuals lead fulfilling lives with appropriate interventions applied early and consistently over time.
Key Takeaways: 22q11.2 Deletion Syndrome- GeneReviews Summary
➤ Most common microdeletion syndrome with variable features.
➤ Cardiac defects are frequent and require early evaluation.
➤ Immunodeficiency due to thymic hypoplasia is common.
➤ Developmental delays and psychiatric disorders often occur.
➤ Genetic testing confirms diagnosis for appropriate management.
Frequently Asked Questions
What is 22q11.2 Deletion Syndrome according to GeneReviews Summary?
22q11.2 Deletion Syndrome is a genetic disorder caused by a microdeletion on chromosome 22 at position q11.2. This deletion disrupts multiple genes essential for development, leading to a wide range of symptoms affecting various organ systems.
How does the 22q11.2 Deletion Syndrome affect the heart?
Cardiac anomalies are common in 22q11.2 Deletion Syndrome, with about 75% of individuals having congenital heart defects. These often include conotruncal malformations such as Tetralogy of Fallot and ventricular septal defects, frequently requiring early surgical intervention.
What causes the genetic deletion in 22q11.2 Deletion Syndrome?
The deletion occurs due to misalignment during meiosis caused by low copy repeats in the 22q11.2 region. This leads to non-allelic homologous recombination, resulting in deletions or duplications of up to 3 million base pairs involving multiple genes.
How does 22q11.2 Deletion Syndrome impact the immune system?
The syndrome often causes thymic hypoplasia or absence, leading to T-cell immunodeficiency. This results in increased susceptibility to infections during infancy and childhood, with severity ranging from mild immune dysfunction to severe immunodeficiency requiring specialized care.
Is 22q11.2 Deletion Syndrome inherited or sporadic?
Most cases of 22q11.2 Deletion Syndrome occur sporadically without family history. However, it can be inherited in an autosomal dominant pattern, meaning a parent with the deletion can pass it on to their child.
Conclusion – 22q11.2 Deletion Syndrome- GeneReviews Summary
The 22q11.2 Deletion Syndrome- GeneReviews Summary delineates a complex genetic condition marked by multisystem involvement stemming from a microdeletion on chromosome 22q11.2. Its hallmark features include congenital heart disease, immunodeficiency due to thymic hypoplasia, hypoparathyroidism-induced hypocalcemia, distinct craniofacial characteristics, neurodevelopmental delays, and increased psychiatric risks later in life.
Diagnosis relies heavily on molecular genetic testing methods like FISH, MLPA, or chromosomal microarray analysis that detect deletions accurately even when clinical presentation varies widely between patients. Treatment remains symptomatic—addressing cardiac defects surgically early on while managing immune deficiencies medically alongside supportive therapies targeting speech development and mental health outcomes.
Genetic counseling is indispensable both pre- and post-diagnosis given inheritance patterns vary between sporadic new mutations versus familial transmission scenarios affecting recurrence risk counseling within families planning future pregnancies.
Ultimately understanding this syndrome through comprehensive summaries such as those provided by GeneReviews empowers clinicians with evidence-based guidance while offering affected individuals tailored care pathways that optimize quality of life despite inherent complexities posed by this multisystem genetic disorder.